Aria Diagnostic launches study of non-invasive prenatal test

Wednesday, January 18, 2012 12:04 PM

As Down syndrome becomes an increasing concern, Aria Diagnostics is launching a comparative study of a non-invasive prenatal test to detect Trisomy 21 (associated with Down synrome) and the standard first-trimester screening test.

Currently in development, Aria’s test is a directed, non-invasive approach to cell-free DNA analysis in maternal blood for evaluation of common fetal trisomies linked to genetic disorders.

The comparative, multicenter clinical trial will enlist 25,000 women, age 18 years or older, who are pregnant with one fetus and planning a hospital delivery. Blood samples will be collected between 10 and 14 weeks, and those receiving the standard first-trimester screening will also receive a nuchal translucency measurement performed via ultrasound. The trial will gather information throughout the pregnancies and collect newborn medical records following birth.

In addition to comparing the performance characteristics of Aria's test with standard first-trimester screening for Trisomy 21, the NEXT (Non-Invasive Chromosomal Examination of Trisomy) study will help define the optimal clinical testing practice for first trimester testing.

The trial is the largest clinical study ever to directly compare first-trimester prenatal testing options.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs